Skip to main content
Journal cover image

Potential of 18F-FDG PET toward personalized radiotherapy or chemoradiotherapy in lung cancer.

Publication ,  Journal Article
Choi, NC; Chun, TT; Niemierko, A; Ancukiewicz, M; Fidias, PM; Kradin, RL; Mathisen, DJ; Lynch, TJ; Fischman, AJ
Published in: Eur J Nucl Med Mol Imaging
June 2013

PURPOSE: We investigated the metabolic response of lung cancer to radiotherapy or chemoradiotherapy by (18)F-FDG PET and its utility in guiding timely supplementary therapy. METHODS: Glucose metabolic rate (MRglc) was measured in primary lung cancers during the 3 weeks before, and 10-12 days (S2), 3 months (S3), 6 months (S4), and 12 months (S5) after radiotherapy or chemoradiotherapy. The association between the lowest residual MRglc representing the maximum metabolic response (MRglc-MMR) and tumor control probability (TCP) at 12 months was modeled using logistic regression. RESULTS: We accrued 106 patients, of whom 61 completed the serial (18)F-FDG PET scans. The median values of MRglc at S2, S3 and S4 determined using a simplified kinetic method (SKM) were, respectively, 0.05, 0.06 and 0.07 μmol/min/g for tumors with local control and 0.12, 0.16 and 0.19 μmol/min/g for tumors with local failure, and the maximum standard uptake values (SUVmax) were 1.16, 1.33 and 1.45 for tumors with local control and 2.74, 2.74 and 4.07 for tumors with local failure (p < 0.0001). MRglc-MMR was realized at S2 (MRglc-S2) and the values corresponding to TCP 95 %, 90 % and 50 % were 0.036, 0.050 and 0.134 μmol/min/g using the SKM and 0.70, 0.91 and 1.95 using SUVmax, respectively. Probability cut-off values were generated for a given level of MRglc-S2 based on its predicted TCP, sensitivity and specificity, and MRglc ≤0.071 μmol/min/g and SUVmax ≤1.45 were determined as the optimum cut-off values for predicted TCP 80 %, sensitivity 100 % and specificity 63 %. CONCLUSION: The cut-off values (MRglc ≤0.071 μmol/min/g using the SKM and SUVmax ≤1.45) need to be tested for their utility in identifying patients with a high risk of residual cancer after standard dose radiotherapy or chemoradiotherapy and in guiding a timely supplementary dose of radiation or other means of salvage therapy.

Duke Scholars

Published In

Eur J Nucl Med Mol Imaging

DOI

EISSN

1619-7089

Publication Date

June 2013

Volume

40

Issue

6

Start / End Page

832 / 841

Location

Germany

Related Subject Headings

  • Treatment Outcome
  • Sensitivity and Specificity
  • Regression Analysis
  • Prospective Studies
  • Probability
  • Positron-Emission Tomography
  • Nuclear Medicine & Medical Imaging
  • Middle Aged
  • Male
  • Lung Neoplasms
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Choi, N. C., Chun, T. T., Niemierko, A., Ancukiewicz, M., Fidias, P. M., Kradin, R. L., … Fischman, A. J. (2013). Potential of 18F-FDG PET toward personalized radiotherapy or chemoradiotherapy in lung cancer. Eur J Nucl Med Mol Imaging, 40(6), 832–841. https://doi.org/10.1007/s00259-013-2348-4
Choi, Noah C., Tristen T. Chun, Andrzej Niemierko, Marek Ancukiewicz, Panos M. Fidias, Richard L. Kradin, Douglas J. Mathisen, Thomas J. Lynch, and Alan J. Fischman. “Potential of 18F-FDG PET toward personalized radiotherapy or chemoradiotherapy in lung cancer.Eur J Nucl Med Mol Imaging 40, no. 6 (June 2013): 832–41. https://doi.org/10.1007/s00259-013-2348-4.
Choi NC, Chun TT, Niemierko A, Ancukiewicz M, Fidias PM, Kradin RL, et al. Potential of 18F-FDG PET toward personalized radiotherapy or chemoradiotherapy in lung cancer. Eur J Nucl Med Mol Imaging. 2013 Jun;40(6):832–41.
Choi, Noah C., et al. “Potential of 18F-FDG PET toward personalized radiotherapy or chemoradiotherapy in lung cancer.Eur J Nucl Med Mol Imaging, vol. 40, no. 6, June 2013, pp. 832–41. Pubmed, doi:10.1007/s00259-013-2348-4.
Choi NC, Chun TT, Niemierko A, Ancukiewicz M, Fidias PM, Kradin RL, Mathisen DJ, Lynch TJ, Fischman AJ. Potential of 18F-FDG PET toward personalized radiotherapy or chemoradiotherapy in lung cancer. Eur J Nucl Med Mol Imaging. 2013 Jun;40(6):832–841.
Journal cover image

Published In

Eur J Nucl Med Mol Imaging

DOI

EISSN

1619-7089

Publication Date

June 2013

Volume

40

Issue

6

Start / End Page

832 / 841

Location

Germany

Related Subject Headings

  • Treatment Outcome
  • Sensitivity and Specificity
  • Regression Analysis
  • Prospective Studies
  • Probability
  • Positron-Emission Tomography
  • Nuclear Medicine & Medical Imaging
  • Middle Aged
  • Male
  • Lung Neoplasms